

Table S1. Clinical outcomes of 16 patients with ALK-rearranged NSCLC treated with crizotinib.

| PD-L1hi group (n=7) | | | | | | PD-L1lo group (n=9) | | | | | |
|---------------------|-------|------|-----------|------|------|---------------------|-------|------|-----------|------|------|
| case | PD-L1 | Treg | CD8+PD-1+ | PF | OS | case | PD-L1 | Treg | CD8+PD-1+ | PF | OS |
| 1 | 50% | high | low | 2.5 | 15.8 | 1 | 0% | low | low | 47.6 | 47.6 |
| 2 | 50% | high | low | 9.8 | 20.2 | 2 | 0% | low | high | 21.7 | 49.8 |
| 3 | 65% | high | high | 2.8 | 24.0 | 3 | 0% | low | low | 44.9 | 52.0 |
| 4 | 65% | low | low | 15.0 | 17.5 | 4 | 0% | low | high | 26.4 | 51.7 |
| 5 | 70% | high | high | 3.2 | 31 | 5 | 0% | high | low | 51.1 | 63.0 |
| 6 | 80% | low | high | 2.9 | 51.4 | 6 | 0% | low | high | 35.5 | 63.7 |
| 7 | 90% | high | low | 10.7 | 15.1 | 7 | 2% | high | low | 8.5 | 45.7 |
| | | | | | | 8 | 5% | low | low | 8.5 | 55.0 |
| | | | | | | 9 | 10% | low | low | 33.5 | 36.3 |